EBV-related malignant tumor specific aptamers and their use in cancer imaging and treatment

By developing high-affinity aptamer for EBV-related NPCs, combining CNBP and MTDH targets, targeted treatment and imaging of nasopharyngeal carcinoma has been achieved, solving the problems of early diagnosis and treatment of nasopharyngeal carcinoma, and significantly improving the treatment efficiency and safety .

CN118922544APending Publication Date: 2024-11-08THE CHINESE UNIVERSITY OF HONG KONG
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202380015639.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-02-09
Filing Date
2023-02-08
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

There are difficulties in diagnosis and treatment of nasopharyngeal carcinoma, especially due to the concealment of the nasopharyngeal and nonspecific symptoms leading to advanced diagnosis. Traditional treatments have acute and advanced toxicity, and existing targeted therapeutic targets are not common, especially Targeted therapy related to undifferentiated nonkeratinized subtype NPCs and EBV infection is difficult to achieve.

Method used

Apt-2019 and Apt-1194, etc., was developed to target EBV-associated NPC cell surface markers, and high-affinity aptamers are enriched through cell-SELEX and in vivo-SELEX techniques to bind to CCHC type Zinc finger nucleic acid binding protein (CNBP) and isomimin (MTDH), used for cancer imaging and targeted therapy, combining fluorescent probes and drug loading for targeted delivery.

Benefits of technology

The specific targeting of EBV-positive NPC cells was achieved, which significantly reduced the tumor growth and migration ability, and significantly improved the efficacy of 5-FU through drug-loaded aptamers, reduced the toxicity to normal tissues, and improved the treatment. efficiency and safety.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure HDA0004911238150000011
    Figure HDA0004911238150000011
  • Figure HDA0004911238150000012
    Figure HDA0004911238150000012
  • Figure HDA0004911238150000021
    Figure HDA0004911238150000021
Patent Text Reader

Abstract

The present invention provides aptamers and compositions thereof for use in methods of cancer imaging and treatment. The aptamer can bind to a target, which includes a CCHC type zinc finger nucleic acid binding protein (CNBP) and a heteromucin (MTDH). The aptamers may be conjugated to various pharmaceutical agents and / or biocompatible imaging probes.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims the benefit of U.S. patent application serial number 63 / 267,737, filed on February 9, 2022, which is incorporated herein by reference in its entirety, including any tables, figures, or drawings. Background Art

[0003] In recent years, proof-of-concept studies of aptamer technology have continuously revealed its excellent functions and great therapeutic potential (1,2). Aptamers can improve the targeting specificity and pharmacokinetic characteristics of conjugated drugs or nanocarriers. To date, one aptamer has been approved by the U.S. Food and Drug Administration (FDA), and ten aptamers have entered clinical trials for the treatment of solid tumors, lymphoma, macular degeneration, coagulation, and inflammation (2).

[0004] Aptamers are short single-stranded oligonucleotides (e.g., DNA, RNA) that bind to the desired target with high affinity and specificity by folding into a tertiary structure. In order to obtain aptamers that can bind specifically to the target, a small number of aptamers are usually selected from the ssDNA library for exponential enrichment with a given target by systematic evolution of ligands (SELEX) (3,4) (3,4). In this way, through 10 to 15 rounds of forward PCR enrichment, 1×10 aptamers that interact with the relevant target can be screened simultaneously. 15 Almost all aptamers selected by SELEX have a dissociation constant (K d ) exhibit high affinity for targets in the micromolar to nanomolar range. Therefore, aptamers are also called "chemical antibodies" and have rapidly become a new type of powerful ligand with good potential in molecular probe development, biosensors, tumor biomarker discovery and drug delivery (3,5-7). Cell-SELEX is a modified SELEX process in which living cells are used as targets for aptamer selection (4). Compared with traditional selection of target purified proteins, cell-SELEX is able to produce aptamers that specifically bind to target molecules on the cell surface in their native conformation. In vivo-SELEX can further enrich aptamers that can accumulate in tumors in mouse models.

[0005] Nasopharyngeal carcinoma (NPC) is a malignant squamous cell tumor that arises in the nasopharynx (8,9). The peak age at diagnosis is in the late 40s and 50s. In Hong Kong, China, NPC is the most common cancer in men under 40 years of age (4). As a result, this endemic disease imposes a socioeconomic burden on these relatively young cancer patients and their families.

[0006] Concurrent chemoradiotherapy remains the mainstay of treatment for primary NPC. In addition, many NPC cases are diagnosed at advanced stages only at stage III or IV due to the occult nature of the nasopharynx and the nonspecificity of initial symptoms (10). To aid in diagnosis, imaging probes that can visualize both primary and metastatic cancer sites are essential.

[0007] In addition, whenever systemic chemotherapy is administered for primary, recurrent, and metastatic cases, patients may experience acute toxicity, including hearing loss, swallowing problems, and other problems, as well as late toxicity, including cranial neuropathy, temporal lobe necrosis, aspiration pneumonia, etc. In order to better treat NPC patients, more effective and less toxic treatment options are needed (8,10).

[0008] Over the past decade, we and others have been working hard to search the translational genome for druggable targets in NPC (11-15). However, druggable molecular targets such as PIK3CA, EGFR, FGFR1 / 2 / 3 / 4, and BRCA1 / BRCA2 / ATM are uncommon in NPC, occurring in only 6% of patients. The low mutational burden of NPC inhibits the potential of targeted therapies that rely on immediately approved drugs.

[0009] The undifferentiated, nonkeratinizing subtype of NPC, which is common in southern China, is almost universally associated with EBV infection (8, 16). In NPC cells, EBV hides in a latent state and expresses only two membrane-bound proteins (LMP1 and LMP2), intracellular RNAs (EBER and EBV-microRNA), and a nuclear protein (EBNA1) required for EBV maintenance and NPC development. LMP1 remains the major oncoprotein in the carcinogenesis of NPC (17, 18). Approximately 30% of NPC tumors express high levels of LMP1 and are associated with poor disease outcomes and fewer genomic mutations (12). We have also proposed a model of NPC clonal evolution driven by EBV infection and progressive genomic changes in the premalignant nasopharyngeal epithelium (11, 16, 18).

[0010] Therefore, there is still a need for aptamers that can specifically target cell surface markers in Epstein-Barr virus (EBV)-associated NPC. Summary of the invention

[0011] The present invention relates to aptamers and compositions thereof for cancer cell imaging and cancer treatment methods. The present disclosure provides nucleic acid sequences of aptamers according to SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3 or oligonucleotides having at least 90% identity with SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3. In certain embodiments, the aptamer can bind to a target, and the target includes CCHC-type zinc finger nucleic acid binding protein (CNBP) and heteromycin (MTDH), etc. In certain embodiments, the aptamer can achieve cancer imaging by connecting the aptamer to a molecular probe (e.g., a fluorescent probe and a positron emission tomography radioactive tracer). In certain embodiments, the aptamer can be used for drug targeting by using the drug-loaded aptamer (e.g., toxic nucleotide analogs and other anticancer nanoparticles). BRIEF DESCRIPTION OF THE DRAWINGS

[0012] The patent or application file contains at least one drawing printed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.

[0013] Figure 1A to Figure 1B . Discovery of Apt-2019 targeting cells expressing LMP1. ( Figure 1A ) Enrichment of aptamers with higher binding affinity to cells expressing LMP1 after 12 rounds of cell-SELEX. The enriched pool of aptamers was sequenced and enriched by similarity. Eight aptamers were selected for FACS analysis of binding affinity to cells expressing LMP1. ( Figure 1B ) The specificity of Apt-2019 binding to LMP1-positive cells was verified by FACS analysis (left) and fluorescence imaging (right).

[0014] FIG. 2A to FIG. 2B . CNBP was identified as the binding target of Apt-2019. ( Figure 2A ) Schematic diagram showing the process of identifying the binding partner of Apt-2019. ( Figure 2B )CNBP was purified and attached to the particles. After binding to FAM-labeled Apt-2019, only the particles labeled with CNBP emitted a high fluorescence signal.

[0015] FIG. 3A to FIG. 3H Apt-2019 was identified as a CNBP-binding aptamer on cells expressing LMP1. Figure 3A) Using non-permeabilized cells, fluorescence microscopy shows cell surface staining of Apt-2019 and CNBP on LMP1-expressing NPC43 (noEBV) cells. Notably, expression of LMP1 in NPC cells can induce expression of CNBP, which can bind to Apt-2019. ( Figure 3B )LMP1 expression can upregulate the expression of CNBP. Figure 3C ) Binding of Apt-2019 was much lower in CNBP knockout cells compared to parental cells. Figure 3D ) Membrane protein lysates, cytoplasmic protein lysates, and nuclear protein lysates were extracted from parental cells and CNBP knockout cells. CNBP was abundantly expressed in the membrane fraction. Figure 3E ) Overexpression of CNBP was found in NPC cell lines and human xenografts. Primary normal nasopharyngeal epithelial cells were immortalized by hTert (the catalytic domain of telomerase). Figure 3F ) High expression of CNBP was detected in primary NPC tissue and xenograft-76 by IHC. High magnification images show abundant CNBP membrane expression. ( Figure 3G ) Knockdown of CNBP by siRNA inhibits proliferation in NPC cells. Figure 3H ) The migration of NPC cells was evaluated by wound healing assay. Knockdown of CNBP inhibited the migration of NPC cells.

[0016] 4A to 4F Apt-1194 and Apt-1798 were identified as targeting aptamers for EBV-positive cell lines. Figure 4A ) shows a schematic diagram of the process of discovering aptamers targeting EBV-positive NPC tumors through a combination of cell-SELEX and in vivo SELEX. Aptamers that preferentially bind to EBV-positive cells were enriched through 12 rounds of cell-SELEX. The aptamer pool was then injected into mice and two more rounds of in vivo SELEX were performed. The enriched aptamers were then sequenced. Apt-1194 and Apt-1798 were the most enriched sequences. ( Figure 4B )Apt-1194 and Apt-1798 can specifically bind to EBV-positive cell lines, but not to EBV-negative cell lines (A549 is a lung cancer cell line; NP460 is an immortalized NP cell line). ( Figure 4C ) Proteins were pulled down from EBV-positive NPC43 cells using Apt-1194 or Apt-library. The proteins pulled down in different ways were purified and identified as MTDH by mass spectrometry and western blot analysis. Figure 4D ) High expression of MTDH was detected in primary NPC tissue and xenograft-76 by IHC. High magnification images show abundant MTDH membrane expression. ( Figure 4E ) Overexpression of MTDH was found in NPC cell lines and human xenografts. Figure 4F )Knockdown of MTDH inhibits proliferation and migration in NPC cells.

[0017] FIG. 5A to FIG. 5G . Characterization of Apt-2019 and Apt-1194. ( Figure 5A ) shows a diagram of a G-quadruplex structure that can be formed by a G-rich aptamer. ( FIG. 5B to FIG. 5C ) Fluorescence enhancement assay (FEA) was used to detect the G-quadruplex formation sequence. Both Apt-2019 and Apt-1194 can form G-quadruplexes in the presence of K+ ions or L+ ions, and then make the ThT ligand emit light. ( Figure 5D )Apt-2019 and Apt-1194 showed much higher serum stability than random aptamer sequences. FIG. 5E to FIG. 5F ) A series of concentrations of FITC-labeled Apt-2019 and Apt-1194 bind to NPC43 overexpressing LMP1 and EBV-positive C666-1, respectively. The equilibrium dissociation constant (Kd) is then calculated. ( Figure 5G ) Apt-2019 was allowed to bind to live NPC cells for 45 min. Internalization of Apt-2019 was verified by Z-stack imaging using confocal microscopy.

[0018] FIG. 6A to FIG. 6B . Apt-2019 and Apt-1194 can specifically target xenografts - C15 and C666-1 tumors, respectively. The aptamers were fluorescently labeled to image their biodistribution in mouse models. In the control aptamer (Apt-NG), all G nucleotides were replaced by C nucleotides to disrupt the G-quadruplex 3-D configuration. ( Fig. 6A ) Accumulation of Apt-2019 was observed in C15 xenografts but not in their control counterparts. ( Figure 6B ) Apt-1194 can also selectively target EBV+ve tumors if compared to the Apt-NG1194 control aptamer. It is not surprising that the fluorescent signal was detected in the liver, as the liver is a site for detoxification and breakdown of harmful substances.

[0019] 7A to 7E . Cytotoxicity of Apt-2019 loaded with 5FU and Apt-1194 loaded with gemcitabine. ( Fig. 7A ) Intrinsic binding of aptamers to gemcitabine or 5-FU. FIG. 7B to FIG. 7C ) Binding affinity of drug-free Apt-2019 and Apt-1194 and drug-loaded Apt-2019 and Apt-1194 to target cells. Both 5-FU and gemcitabine-bound aptamers maintained binding affinity. FIG. 7D to FIG. 7E ). In vitro toxicity of drug-loaded aptamers to target cells. Apt-2019-5FU and Apt-1194-gem can inhibit the growth of LMP1+ve and EBV+ve NPC cells, respectively.

[0020] FIG. 8A to FIG. 8D . Loading 5-FU into Apt-2019 significantly reduced the effective therapeutic dose by >10-fold. ( Fig. 8A )Xeno113-bearing mice were treated with DPBS, free 5-FU, and Apt-2019-5FU by tail vein injection. Apt-2019 contains 13 thymine nucleotides, and we have exchanged all of them for 5-FU. To demonstrate that Apt-2019 can enhance the delivery of 5-FU to targeted tumors, we used a 5-FU dose that was 11.5 times the normal therapeutic dose. The same molar concentration of 5-FU was used in the free 5-FU and Apt-2019-5FU treatment groups. Free 5-FU was unable to significantly inhibit tumor growth, while Apt-2019-5FU could inhibit tumor growth. The morphology of the spleen, liver, and kidneys ( Figure 8B ) and the body weight of mice ( Figure 8C ) had no observable changes. Fig.8D )Apt-2019-5FU showed effective inhibitory effect on the growth of XenoC15 with high expression of LMP1.

[0021] Sequence Description

[0022] SEQ ID NO: 1: Apt-2019 aptamer

[0023] SEQ ID NO: 2: Apt-1194 aptamer

[0024] SEQ ID NO: 3: Apt-1798 aptamer

[0025] SEQ ID NO:4: Apt-NG 2019(14-63) Aptamers

[0026] SEQ ID NO:5: Apt-NG 1194(1-58) Aptamers DETAILED DESCRIPTION

[0027] Selected Definitions

[0028] As used herein, the singular forms "a", "an", and "the" include the plural forms unless the context clearly dictates otherwise. In addition, to the extent that the terms "including", "includes", "having", "has", "with" or variations thereof are used in the specification and / or claims, these terms are intended to be inclusive in a manner similar to the term "comprising". The transitional terms / phrases (and any grammatical variations thereof) "comprising", "comprises", "comprise", "consisting essentially of", "consists essentially of", "consisting", and "consists" are used interchangeably.

[0029] The phrase "consisting essentially of" or "consists essentially of" means that a claim includes embodiments that include the specified materials or steps and that do not materially affect the basic and novel characteristics of the claim.

[0030] The term "approximately" refers to the acceptable error range of a particular value determined by a person of ordinary skill in the art, and the range depends on how to measure the value, i.e., the limitation of the measurement system. In the case of compositions containing a certain amount of ingredients using the term "approximately", these compositions contain a specified amount of ingredients, and the variation (error range) of their values ​​(X ± 10%) is 0% to 10%. In other cases, the term "approximately" provides a variation (error range) of 0% to 10% in a given value (X ± 10%). Obviously, this variation represents a range of 10% above or below a given value, for example, X ± 1%, X ± 2%, X ± 3%, X ± 4%, X ± 5%, X ± 6%, X ± 7%, X ± 8%, X ± 9% or X ± 10%.

[0031] In the present disclosure, the scope is stated in a shorthand manner to avoid having to list and describe each value in the scope at length. Where appropriate, any appropriate value in the scope can be selected as the upper limit, lower limit or end point of the scope. For example, the scope of 0.1 to 1.0 represents the endpoint values ​​0.1 and 1.0, and the intermediate value 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, and all intermediate ranges included in 0.1 to 1.0, such as 0.2 to 0.5, 0.2 to 0.8, 0.7 to 1.0, etc. It is conceivable that there are at least two significant figures in a range, for example, the scope of 5 to 10 represents all values ​​between 5.0 and 10.0 and between 5.00 and 10.00, including the endpoint values. When using scope in this article, the combination and sub-combination of scope (for example, the sub-range in the disclosed range) and the specific embodiment thereof are explicitly included.

[0032] As used herein, the term "subject" refers to an animal to which the benefit provided by the delivery of a therapeutic compound is desired or desired. The animal may be a human, pig, horse, goat, cat, mouse, rat, dog, ape, fish, chimpanzee, orangutan, guinea pig, hamster, cow, sheep, bird, chicken, and any other vertebrate or invertebrate, among others. These benefits may include, but are not limited to, treating a health condition, disease, or condition; preventing a health condition, disease, or disorder; immune health; enhancing the function of a body organ, tissue, or system. In the context of the present invention, it is preferred that the subject is a human. The subject may be a subject of any age or developmental stage, including an infant, toddler, teenager, adult, or elderly.

[0033] As used herein, the terms "therapeutically effective amount," "therapeutically effective dose," "effective amount," and "effective dose" refer to an amount or dose of a compound or composition that, when administered to a subject, is capable of treating or ameliorating a condition, disease, or disorder in a subject, or is capable of enhancing the health or function of an organ, tissue, or body system. In other words, the amount is a "therapeutically effective" amount when administered to a subject. The actual amount will vary depending on a variety of factors, including, but not limited to, the specific condition, disease, or disorder being treated or ameliorated; the severity of the condition; the specific organ, tissue, or body system whose health or function is desired to be enhanced; the patient's weight, height, age, and health; and the route of administration.

[0034] As used herein, the term "treat" refers to eliminating, reducing, ameliorating or reversing the signs or symptoms of a health condition, disease or disorder to any extent, including but not requiring complete cure of the condition, disease and disorder. Treatment can be curing, ameliorating or partially alleviating the condition. "Treatment" can also include improving or enhancing a condition or feature, for example, bringing the function of a particular system in the body to a higher state of health or homeostasis.

[0035] As used herein, "preventing" a health condition, disease, or disorder means avoiding, delaying, preventing, or minimizing the onset of specific signs or symptoms of that condition, disease, or disorder. Prevention can be absolute or complete, but is not necessarily so; that is, signs or symptoms may still develop later. Prevention can include reducing the severity of the onset of such a condition, disease, or disorder, and / or inhibiting the progression of the condition, disease, disorder to a more serious condition, disease, or disorder.

[0036] In some embodiments of the present invention, the method includes administering multiple doses of the compounds of the present invention. The method may include administering 1 therapeutically effective dose, 2 therapeutically effective doses, 3 therapeutically effective doses, 4 therapeutically effective doses, 5 therapeutically effective doses, 6 therapeutically effective doses, 7 therapeutically effective doses, 8 therapeutically effective doses, 9 therapeutically effective doses, 10 therapeutically effective doses, 15 therapeutically effective doses, 20 therapeutically effective doses, 25 therapeutically effective doses, 30 therapeutically effective doses, 35 therapeutically effective doses, 40 therapeutically effective doses or more therapeutically effective doses of compositions comprising compounds of the present invention as described herein. In some embodiments, the dose is administered within 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 10 days, 14 days, 21 days, 30 days or more than 30 days. The frequency and duration of administering multiple dose compositions are, for example, administering aptamers or treating and / or imaging cancer cells. In addition, treating a subject with a therapeutically effective amount of a compound of the present invention may include a single treatment or may include a series of treatments. It should also be understood that the effective dose of the compound used for treatment may increase or decrease during a specific treatment period. Variations in dosage may be caused and become apparent from the results of diagnostic assays or imaging techniques known in the art for detecting tumor size.In some embodiments of the invention, the method comprises administering the compound several times a day, including but not limited to 2 times a day, 3 times a day, and 4 times a day.

[0037] As used herein, an "isolated" or "purified" compound is substantially free of other compounds. In certain embodiments, the purified compound is at least 60% by weight (dry weight) of the compound of interest. Preferably, the preparation is at least 75%, more preferably at least 90%, and most preferably at least 99% by weight of the compound of interest. For example, the purified compound is at least 90%, 91%, 92%, 93%, 94%, 95%, 98%, 99%, or 100% by weight (w / w) of the desired compound. Purity is measured by any suitable standard method such as column chromatography, thin layer chromatography, or high performance liquid chromatography (HPLC) analysis.

[0038] By "reduced" is meant a negative change of at least 1%, 5%, 10%, 25%, 50%, 75% or 100%.

[0039] By "increase" is meant a positive change of at least 1%, 5%, 10%, 25%, 50%, 75% or 100%.

[0040] As used herein, "drug" refers to a chemical compound manufactured for use as a medicine and / or therapeutic.

[0041] The terms "label," "detectable marker," "detectable moiety," and the like refer to compositions detectable by spectroscopic, photochemical, biochemical, immunochemical, chemical, or other physical means. For example, useful labels include fluorescent dyes (fluorophores), luminescent agents, electron-dense reagents, enzymes (e.g., as commonly used in ELISA), biotin, enzymes acting on substrates (e.g., horseradish peroxidase), thiols, digoxigenin, 32 P and other isotopes, haptens, and detectable proteins by conjugating radioactive labels to aptamers, etc. The term includes combinations of individual labeling agents, such as combinations of fluorophores that provide unique detectable features at a specific wavelength or combination of wavelengths. In the case of detecting nucleic acids (e.g., target sequences), aptamers are typically labeled with radioisotopes, fluorescent markers (fluorophores), or luminescent agents.

[0042] As used herein, the term "nucleic acid" or "polynucleotide" refers to deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) and polymers thereof in single-stranded or double-stranded form. Unless otherwise specified, the term includes nucleic acids containing known analogs of natural nucleotides, which have similar binding properties to reference nucleic acids and are metabolized in a manner similar to naturally occurring nucleotides. Unless otherwise specified, a specific nucleic acid sequence also implicitly includes conservatively modified variants thereof (e.g., degenerate codon substitutions), alleles, orthologs, single nucleotide polymorphisms (SNPs), and complementary sequences as well as sequences explicitly specified. Specifically, degenerate codon substitutions can be achieved by generating sequences in which the third position of one or more selected (or all) codons is substituted with mixed bases and / or deoxyinosine residues (Batzer et al., Nucleic Acids Res. 19:5081 (1991); Ohtsuka et al., J. Biol. Chem. 260:2605-2608 (1985); and Rossolini et al., Molecular and Cellular Probes 8:91-98 (1994)). The term nucleic acid can be used interchangeably with gene, cDNA, and mRNA encoded by a gene.

[0043] As used herein, the term "identical" or percentage "identity", in the case of describing two or more polynucleotides or amino acid sequences, refers to the comparison and alignment of maximum correspondence within a comparison window or a specified region, or can be measured using one of the following sequence alignment algorithms or by manual alignment and visual inspection, two or more sequences or subsequences are identical, or have a specific percentage of amino acid residues or nucleotides that are identical (e.g., the nucleotide aptamers used in the method of the present invention have at least 70% sequence identity with different aptamer sequences or their complementary sequences, preferably 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity). Such sequences are subsequently referred to as "substantially identical". With respect to polynucleotide sequences, this definition also refers to the complementarity of test sequences.

[0044] The recitation of a list of chemical groups in any definition of a variable herein includes definitions of that variable as any single group or combination of the listed groups. The recitation of an embodiment for a variable or aspect herein includes that embodiment as any single embodiment or in combination with any other embodiment or portion thereof.

[0045] Any composition or method provided herein can be combined with one or more of any other compositions and methods provided herein.

[0046] Other features and advantages of the present invention will be apparent from the following detailed description of the preferred embodiments thereof, and from the claims.

[0047] Preparation of aptamers and compositions thereof

[0048] In certain embodiments, the present invention provides one or more aptamers that bind to a target nucleic acid or protein, wherein the aptamers include CCHC-type zinc finger nucleic acid binding protein (CNBP) and / or metahesin (MTDH), etc.

[0049] Typically, an aptamer can be at least 10 base pairs in length, more often at least about 15 base pairs, about 20 base pairs, about 25 base pairs, about 30 base pairs, about 35 base pairs, about 40 base pairs, about 45 base pairs, about 50 base pairs, about 55 base pairs, about 60 base pairs, about 65 base pairs, about 70 base pairs, about 75 base pairs, about 80 base pairs, about 85 base pairs, about 90 base pairs, about 95 base pairs, about 100 base pairs, about 110 base pairs, about 120 base pairs, about 130 base pairs, about 140 base pairs, about 150 base pairs, or more.

[0050] In preferred embodiments, one aptamer, two aptamers, three aptamers, four aptamers, five aptamers, six aptamers, seven aptamers, eight aptamers, nine aptamers, ten aptamers, or more aptamers can be used in the compositions and methods of the present invention. In certain embodiments, the aptamer can be according to SEQ ID NO: 1 (Apt-2019 aptamer: ATCCAGAGTGACGCAGCAGAATGGGTGGGATTCCTCAGAGGGGTTGGTGAGTTTGTGATGGACACGGTGGCTTAGT), SEQ ID NO: 2 (Apt-1194 aptamer: ATCCAGAGTGACGCAGCACCGAGCGAGTTGGTTTGCTGCGGTGGGCAGAGAGGTGGGGTGGACACGGTGGCTTAGT), SEQ ID NO: 3 (Apt-1798 aptamer: ATCCAGAGTGACGCAGCAATCGTGGACCTGGCTGTGGTTTGCTGAGGTGGGCGCCAATTGGACACGGTGGCTTAGT), or a nucleotide sequence of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO:3 has a sequence that is at least about 75%, about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100% identical.

[0051] In certain embodiments, the aptamers herein may include any useful label, including a thiol group, biotin or an enzyme, or a fluorescent label and a quenching label at any useful position in the nucleic acid sequence (e.g., at the 3′-end and / or the 5′-end). Exemplary fluorescent labels include quantum dots or fluorophores. Examples of fluorescent labels used in this method include fluorescein, 6-FAM TM (Applied Biosystems, Carlsbad, Calif.), TET TM (AppliedBiosystems, Carlsbad, Calif.), VIC TM (Applied Biosystems, Carlsbad, Calif.), MAX, HEX TM (Applied Biosystems, Carlsbad, Calif.), TYE TM (ThermoFisher Scientific, Waltham, Mass.), TYE665, TYE705, TEX, JOE, Cy TM(Amersham Biosciences, Piscataway, N.J.) Dyes (Cy2, Cy3, Cy3B, Cy3.5, Cy5, Cy5.5, Cy7), (Molecular Probes, Inc., Eugene, Ore.) Texas Red-X, (Molecular Probes, Inc., Eugene, Ore.) Dyes (AlexaFluor 350, AlexaFluor 405, AlexaFluor 430, AlexaFluor 488, AlexaFluor500, AlexaFluor 532, AlexaFluor 546, AlexaFluor 568, AlexaFluor 594, AlexaFluor 610, AlexaFluor 633, AlexaFluor 647, AlexaFluor 660, AlexaFluor680, AlexaFluor 700, AlexaFluor 750), DyLight TM (ThermoFisher Scientific, Waltham, Mass.) Dyes (DyLight350, DyLight 405, DyLight 488, DyLight 549, DyLight 594, DyLight 633, DyLight 649, DyLight 755), ATTO TM (ATTO-TEC GmbH, Siegen, Germany) Dyes (ATTO 390, ATTO 425, ATTO465, ATTO 488, ATTO 495, ATTO 520, ATTO 532, ATTO 550, ATTO 565, ATTO Rhol01, ATTO590, ATTO 594, ATTO 610, ATTO 620, ATTO 633, ATTO 635, ATTO 637, ATTO 647, ATTO 647N, ATTO 655, ATTO 665, ATTO 680, ATTO 700, ATTO 725, ATTO 740), (Molecular Probes, Inc., Eugene, Oreg.) Dye (BODIPY FL, BODIPY R6G, BODIPY TMR, BODIPY 530 / 550, BODIPY 558 / 568, BODIPY 564 / 570, BODIPY 576 / 589, BODIPY 581 / 591, BODIPY 630 / 650, BODIPY 650 / 665), HiLyte Fluor TM (AnaSpec, Fremont, Calif.) Dye (HiLyte Fluor 488, HiLyte Fluor 555, HiLyte Fluor 594, HiLyte Fluor 647, HiLyte Fluor 680, HiLyte Fluor 750), AMCA, AMCA-S, Blue (Molecular Probes, Inc., Eugene, Oreg.), Cascade Yellow, Coumarin, Hydroxycoumarin, Rhodamine Green TM -X (Molecular Probes, Inc., Eugene, Oreg.), Rhodamine Red TM -X (Molecular Probes, Inc., Eugene, Oreg.), Rhodamine 6G, TM R.ABY TM (Applied Biosystems, Carlsbad, Calif.), TAMRA TM (Applied Biosystems, Carlsbad, Calif.), 5-TAMRA, JUN TM (Applied Biosystems, Carlsbad, Calif.), ROX TM (Applied Biosystems, Carlsbad, Calif.), (Life Technologies, Grand Island, NY), Oregon Green 500, 700 (Li-Cor Biosciences, Lincoln, Nebr.), IRDye 800, WeIIRED D2, WeIIRED D3, WeIIREDD4, and 640 (Roche Diagnostics GmbH, Mannheim, Germany). In some embodiments, an extinction coefficient greater than 50,000 M may be used.-1 cm -1 and luminescent fluorophores that are appropriately spectrally matched to the fluorescence detection channels.

[0052] In certain embodiments, a fluorescently labeled aptamer is included in the reaction mixture and a fluorescently labeled reaction product is produced. The fluorophore used as a label to produce the fluorescently labeled aptamer included in the embodiments of the methods and compositions of the present invention can be any one of a number of fluorophores, including but not limited to: 4-acetamido-4'-isothiocyanatostilbene-2,2'disulfonic acid; acridine and derivatives, such as acridine and isothiocyanate acridine; 4-amino-N-[3-(ethylenesulfonyl)phenyl]phthalimide-3,5-disulfonic acid, Lucifer Yellow VS; N-(4-phenylamino-1-naphthyl)maleimide; anthranilamide, brilliant yellow; BIODIPY fluorophore (4,4-difluoro-4-boron-3a,4a-diaza- symmetric indole); coumarin and derivatives, such as coumarin, 7-amino-4-methylcoumarin (AMC, coumarin 120), 7-amino-4-trifluoromethylcoumarin (coumarin 151); cyanogen; DAPDXYL sulfonyl chloride; 4,6-diamino-2-phenylindole (DAPI); (5',5"-dibromopyrogallolsulfonphthalein (bromopyrogallol red); 7-diethylamino-3-(4'-isothiocyanatophenyl)-4-methylcoumarin; diethylenetriaminepentaacetic acid; 4,4'-diisothiocyanatodihydro-stilbene-2,2'-disulfonic acid; 4,4'-diisothiocyanatostilbene-2,2'-disulfonic acid acid; 5-[dimethylamino]naphthalene-1-sulfonyl chloride (DNS, dansyl chloride); 4-(4'-dimethylaminophenylazo)benzoic acid (DABCYL); 4-dimethylaminophenylazophenyl-4'-isothiocyanate (DABITC); EDANS (5-[(2-aminoethyl)amino]naphthalene-1-sulfonic acid), eosin and derivatives such as eosin isothiocyanate; erythrosin and derivatives such as erythrosin B and erythrosin B isothiocyanate; ethidium bromide, such as ethidium bromide; fluorescein and derivatives such as 5-carboxyfluorescein (FAM), hexachlorofluorescein, 5-(4,6-dichlorotriazinyl)aminofluorescein ( DTAF), 2',7'-dimethoxy-4',5'-dichloro-6-carboxylic acid fluorescein (JOE) and fluorescein isothiocyanate (FITC); fluoroamine; green fluorescent protein and derivatives such as EBFP, EBFP2, ECFP and YFP; IAEDANS (5-({2-[(iodoacetyl)amino]ethyl}amino)naphthalene-1-sulfonic acid), malachite green isothiocyanate; 4-methylumbelliferone; o-cresolphthalein; nitrotyrosine; pararosaniline; phenol red; B-phycoerythrin; o-phthalaldehyde; pyrene and derivatives such as pyrene butyrate, 1-pyrenesulfonyl chloride and 1-pyrene butyric acid succinimidyl ester; QSY 7; QSY 9; Reaction Red 4 ( Brilliant Red 3B-A); rhodamine and derivatives, such as 6-carboxy-X-rhodamine (ROX), 6-carboxyrhodamine (rhodamine 6G), rhodamine isothiocyanate, lissamine rhodamine B chloride, rhodamine B, rhodamine 123, sulforhodamine B, sulforhodamine 101 and the sulfonyl chloride derivative of sulforhodamine 101 (Texas Red); N,N,N',N-tetramethyl-rhodamine carboxylate (TAMRA); tetramethylrhodamine; tetramethylrhodamine isothiocyanate (TRITC); riboflavin; rhodamine; and terbium chelate derivatives.

[0053] Exemplary quenching labels include fluorophores, quantum dots, metal nanoparticles and other related labels. Suitable quenchers include Black Hole -1 (Biosearch Technologies, Novato, CA), BHQ-2, Dabcyl, Iowa FQ (Integrated DNA Technologies, Coralville, IA), IowaBlackRQ, QXL TM (AnaSpec, Fremont, CA), QSY 7, QSY 9, QSY 21, QSY 35, IRDye QC, BBQ-650, Atto540Q, Atto 575Q, Atto 575Q, MGB 3'CDPI3 and MGB-5'CDPI3. In one example, the term "quencher" refers to a substance that reduces the emission of a fluorescent donor when it is in close proximity to the fluorescent donor. In a preferred embodiment, the quencher is within 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 nucleotide bases of the fluorescent label. Fluorescence is quenched when the fluorescence emitted by a fluorophore is significantly reduced, such as by 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99% or more.

[0054] In certain embodiments, the concentration of the aptamer in the compositions and methods of use is about 1 pM to about 1 M, about 1 nM to about 10 mM, about 0.01 μM to about 100 μM, about 0.1 μM to about 100 μM, about 0.1 μM to about 50 μM, about 0.1 M to about 20 μM, or about 1 μM to about 20 μM.

[0055] In one embodiment, the composition of the present invention is formulated into oral consumables, such as food, capsule, pill or drinkable liquid. Orally deliverable drugs are any physiologically active substances delivered by initial absorption in the gastrointestinal tract or entering the oral mucosa. The composition of the present invention can also be formulated into a solution, which can be applied by intravenous, intraperitoneal, intramuscular, intrathecal or subcutaneous injections. In other embodiments, the subject's composition is formulated into a patch for application via the skin or is directly applied to the skin to produce a local or systemic effect. The composition can be applied via sublingual, oral, rectal or vaginal modes. In addition, the composition can be sprayed into the nose to be absorbed by the nasal membrane, atomized, inhaled orally or nasally or in the eyes or ears.

[0056] The oral consumable according to the present invention is any preparation or composition suitable for consumption, nutrition, oral hygiene or entertainment, and is a product for introduction into the oral cavity of a human or animal for a certain period of time and then swallowed (e.g., food or pills ready for consumption) or taken out of the oral cavity again (e.g., chewing gum or oral hygiene products or medical mouthwashes). Although an orally deliverable drug can be formulated into an oral consumable, and an oral consumable can include an orally deliverable drug, the two terms are not meant to be used interchangeably herein.

[0057] Orally consumable products include all substances or products intended for ingestion by humans or animals in a processed, semi-processed or unprocessed state. This also includes substances that are added to orally consumable products (especially foods and pharmaceuticals) during production, handling or processing and are intended for introduction into the oral cavity of humans or animals.

[0058] Oral consumables may also include substances intended to be swallowed by humans or animals and then digested in an unmodified, prepared or processed state. Thus, oral consumables according to the present invention may also include a shell, coating or other packaging intended to be swallowed with the product or intended to be swallowed.

[0059] In one embodiment, the oral consumable is a capsule, pill, syrup, emulsion or liquid suspension containing the desired oral deliverable substance. In one embodiment, the oral consumable may include an oral deliverable substance in powder form that may be mixed with water or another liquid to generate a drinkable oral consumable.

[0060] In some embodiments, the oral consumables according to the present invention may include one or more preparations for providing nutrition or pleasure. These include in particular baked goods (such as bread, dry biscuits, cakes and other pastries), candies (such as chocolate, chocolate bar products, other bar products, pectin, coated tablets, hard caramel, toffee and caramel, and chewing gum), alcoholic or non-alcoholic beverages (such as cocoa, coffee, green tea, black tea, black tea or green tea beverages rich in green tea or black tea extracts, red date tea, other herbal teas, lemonade containing fruits, isotonic drinks, soft drinks, nectar, fruit and vegetable juices and fruit juice preparations or vegetable juice preparations), fast food. instant beverages (such as instant cocoa drinks, instant tea drinks and instant coffee drinks), meat products (such as ham, fresh or raw sausage preparations, and seasoned fresh meat or cured fresh meat or bacon products), eggs or egg products (for example, dried whole eggs, egg whites and egg yolks), cereal products (such as breakfast cereals, cereal bars and precooked instant rice products), dairy products (such as whole milk drinks or reduced-fat milk drinks or fat-free milk drinks, rice pudding, yogurt, kefir, cream cheese, soft cheese, hard cheese, milk powder, whey , butter, buttermilk and partially or completely hydrolyzed products containing milk protein), soy protein or other soy fraction products (such as soy milk and products prepared therefrom, beverages containing isolated or enzyme-treated soy protein, beverages containing soy flour, soy lecithin-containing products, fermented products such as tofu or tempeh made therefrom, and mixtures with fruit preparations and optional seasoning substances), fruit preparations (such as jam, fruit ice cream, fruit sauce and fruit fillings), vegetable preparations (such as ketchup, sauces, dried vegetables, deep-frozen vegetables, pre-cooked vegetables and cooked vegetables), snack products (such as baked potato chips or fried potato chips (potato chips) or potato dough products and corn- or peanut-based extrudates), products based on fats and oils or their emulsions (such as mayonnaise, flavored mayonnaise and condiments), other ready-to-eat meals and ready-to-eat soups (such as dry soups, instant soups and pre-cooked soups), seasonings (such as hand-sprinkled seasonings), sweetener compositions (such as sweetener tablets, sweetener powders and other preparations for sweetening or whitening beverages or other foods). The composition of the present invention may also be used as a semi-finished product for the production of other compositions for providing nutrition or pleasure.

[0061] The composition of the present invention may further include one or more pharmaceutically acceptable carriers and / or excipients, and may be formulated into solid, semisolid, liquid or gaseous forms, such as tablets, capsules, powders, granules, ointments, solutions, suppositories, injections, inhalants and aerosol preparations.

[0062] As used herein, the term "pharmaceutically acceptable" means compatible with the other ingredients of the pharmaceutical composition and not deleterious to the recipient thereof.

[0063] Carriers and / or excipients according to the present invention may include any and all solvents, diluents, buffers (e.g., neutral buffered saline, phosphate buffered saline or optionally Tris-HCl, acetate buffer or phosphate buffer), oil-in-water emulsions or water-in-oil emulsions, aqueous compositions with or without organic co-solvents suitable for IV use, etc., solubilizers (e.g., polysorbate 65, polysorbate 80), colloids, dispersion media, carriers, fillers, chelating agents (e.g., EDTA or glutathione), amino acids (e.g., glycine), proteins, disintegrants, binders, lubricants, wetting agents, emulsifiers, sweeteners, colorants, flavoring agents, fragrances, thickeners (e.g., carbomer, gelatin or sodium alginate), coatings, preservatives (e.g., thimerosal, benzyl alcohol, polyquaternium), antioxidants (e.g., ascorbic acid, sodium metabisulfite), tonicity control agents, absorption delaying agents, adjuvants, bulking agents (e.g., lactose, mannitol), and the like. The use of carriers and / or excipients is well known in the pharmaceutical and supplement arts. Except insofar as any conventional media or formulation is incompatible with the targeted health promoting substance or composition, a carrier or excipient is contemplated for use in the compositions of the present invention.

[0064] In one embodiment, the composition of the present invention can be made into aerosol preparations so that it can be atomized or inhaled. Suitable pharmaceutical preparations used in aerosol or spray form are powders, particles, solutions, suspensions or emulsions, etc. Oral vaporization sprays or nasal vaporization sprays or inhalation application preparations can also be prepared with carriers, and the carriers include saline, polyethylene glycol or glycol, DPPC, methylcellulose, or with a mixture of powdered dispersants or fluorocarbons. Aerosol preparations can be put into pressurized propellants, such as dichlorodifluoromethane, propane, nitrogen, fluorocarbons and / or other solubilizing agents or dispersants known in the art. Exemplarily, delivery can be carried out by using any other device in disposable delivery devices, sprayers, breath-activated powder inhalers, aerosol metered-dose inhalers (MDI) or numerous sprayer delivery devices available in the art. In addition, spray tents can also be used or directly applied by endotracheal intubation.

[0065] In one embodiment, the composition of the present invention can be formulated into a solution or suspension for administration by injection, etc. The solution or suspension may contain a suitable non-toxic, parenterally acceptable diluent or solvent (e.g., mannitol, 1,3-butylene glycol, water, Ringer's solution, or isotonic sodium chloride solution), or a suitable dispersant or wetting agent and suspending agent (e.g., sterile oil, non-irritating oil, fixed oil) including synthetic monoglycerides or diglycerides, and fatty acids including oleic acid. An illustrative example of a carrier for intravenous use includes a mixture of 10% USP ethanol, 40% USP propylene glycol or polyethylene glycol 600, and the remainder USP water for injection (WFI). Other illustrative carriers for intravenous use include 10% USP ethanol and USP WFI; 0.01-0.1% triethanolamine in USP WFI; or 0.01-0.2% dipalmitoylphosphatidylcholine in USP WFI; and 1-10% squalene or parenteral plant water-in-oil emulsions. Aqueous or saline solutions as well as aqueous glucose and glycerol solutions can be preferably used as carriers, particularly for injectable solutions. Illustrative examples of carriers for subcutaneous or intramuscular use include phosphate buffered saline (PBS) solutions, 5% glucose in WFI and 0.01-0.1% triethanolamine in 5% glucose or 0.9% sodium chloride in USP WFI, or 10% USP ethanol, 40% propylene glycol 1 to 2 or 1 to 4 mixtures, and the balance is an acceptable isotonic solution (e.g. 5% glucose or 0.9% sodium chloride); or 0.01-0.2% dipalmitoylphosphatidylcholine and 1-10% squalene in USP WFI or parenteral vegetable oil-in-water emulsions.

[0066] In one embodiment, the composition of the present invention can be formulated to be applied by topical application to the skin, for example as a topical composition including rinses, sprays or drops, emulsions, gels, ointments, creams, foams, powders, solids, sponges, tapes, steam, pastes, tinctures, or using transdermal patches. In addition to any of the pharmaceutically active carriers, suitable formulations for topical use may also include moisturizers such as carnauba wax, cetyl alcohol, cetyl ester wax, emulsifying wax, aqueous lanolin, lanolin, lanolin alcohol, microcrystalline wax, paraffin, petrolatum, polyethylene glycol, stearic acid, stearyl alcohol, white beeswax or yellow beeswax, etc. In addition, the composition may contain a humectant (e.g., glycerol, propylene glycol, polyethylene glycol, sorbitol solution and 1,2,6-hexanetriol) or a penetration enhancer (e.g., ethanol, isopropanol or oleic acid).

[0067] Administration of aptamers

[0068] In certain embodiments, the aptamer can be administered to a subject. Any administration method that allows the aptamer to contact cells of the subject, particularly cancer cells or tumor cells (including oral, intravenous, intranasal, intraperitoneal, intramuscular, intrathecal or subcutaneous methods, etc.) is contemplated in the subject method. In a preferred embodiment, the aptamer can be administered intravenously.

[0069] In certain embodiments, the aptamer may contact healthy cells and / or tumor cells or cancer cells of the subject. In certain embodiments, the aptamer may contact cells in the nasopharynx, including nasopharyngeal cancer cells. In certain embodiments, the aptamer may inhibit nasopharyngeal carcinoma, pancreatic cancer, gastric cancer, breast cancer and other solid tumors. The aptamer may bind to proteins on the surface of the subject's cells (including cancer cells, etc.). In certain embodiments, the protein may be CNBP and / or MTDH. In certain embodiments, the aptamer may be conjugated to drugs such as nucleoside analogs or biocompatible imaging probes. In certain embodiments, aptamer-drug conjugates may inhibit the growth of tumor cells.

[0070] Use of aptamers as molecular probes for in vivo tumor visualization.

[0071] Early detection, accurate diagnosis, and prediction of disease progression are crucial for optimal treatment planning. In current clinical practice, positron emission tomography-computed tomography (PET-CT) using 18F-FDG provides comprehensive information on anatomy and metabolism in tumor examination.

[0072] In certain embodiments, aptamers, particularly aptamers according to SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3, or aptamers having at least 90% identity to SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3, can be labeled with a variety of biocompatible imaging probes (e.g., radioactive tracers compatible with PET scanning). Labeling of aptamers has been described by Jacobson O et al., PET imaging of glycoprotein-C using single-stranded DNA aptamers with radioactive labels (J Nucl Med. 2015 Apr; 56(4): 616-21. Doi: 10.2967 / jnumed.114.149484. Epub 2015 Feb 19. PMID: 25698784), which is incorporated by reference in its entirety. Jacobsen et al. described the radiosynthesis of 18F-fluorobenzoyl (18F-FB) and 64Cu-NOTA aptamers, as well as 18F-labeled 4-fluorobenzoic acid N-succinimidyl ester (18F-SFB) and 64Cu-labeled S-2-(4-isothiocyanatobenzyl)-1,4,7-triazacyclononane-1,4,7-triacetic acid (64Cu-SCN-Bn-NOTA), which were then linked to the aptamers. In certain embodiments, radioactive tracers that can be used include tritium, carbon-11, carbon-14, oxygen-15, fluorine-18, copper-64, phosphorus-32, sulfur-35, technetium-99, iodine-123, gallium-67, antimony-124, bromine-82, iodine-125, iodine-131, iridium-192, scandium-46, manganese-56, sodium-24, technetium-99m, silver-110m, argon-41, and xenon-133. In certain embodiments, the biocompatible imaging probe can be 18F-FDG, 64Cu-NOTA, 11C-methionine, or 11C-choline. In certain embodiments, aptamers labeled with one or more imaging probes can be used in methods for identifying tumor cells, such as EBV / LMP1 positive tumor cells and other cancer cell types that show overexpression of aptamer-targeted surface molecules. In certain embodiments, PET can be used as a nuclear imaging test for identifying tumor cells. PET scanning can be combined with computed tomography (CT) and radioactive tracer-labeled aptamers. Prior to the PET scan, the aptamer (labeled with a radioactive tracer) can be injected into the subject's blood. After the tracer is absorbed by the subject, the subject can be placed in a PET scanner. The tracer is a radioactive labeled tracer, which means that the gamma rays it emits can be detected by the PET scanner. The computer collects the information emitted by the tracer and displays it on a CT cross-section for identifying tumor cells with higher accumulation of tracer-labeled aptamers. In certain embodiments, the aptamer-targeted surface molecule is CNBP and / or MTDH.

[0073] In certain embodiments, other cancer cell types that display overexpression of aptamer-targeted surface molecules include nasopharyngeal carcinoma, pancreatic cancer, gastric cancer, bladder cancer, colorectal cancer, endometrial cancer, kidney cancer, leukemia, liver cancer, lung cancer, melanoma, and breast cancer, among others.

[0074] Aptamer-based chemotherapeutic and nanoparticle delivery as an effective therapeutic strategy for cancer.

[0075] In certain embodiments, the drug compound or drug can be conjugated to an aptamer, particularly an aptamer according to SEQ ID NO 1, SEQ ID NO: 2 or SEQ ID NO: 3 or having at least 90% identity to SEQ ID NO 1, SEQ ID NO: 2 or SEQ ID NO: 3. In certain embodiments, the compound can be labeled at the 5' end or the 3' end of the aptamer. In certain embodiments, when toxic nucleoside analogs such as gemcitabine or fluorouracil are used, these analogs can be exchanged with the nucleotides of the aptamer. In certain embodiments, the drug may be a toxic nucleoside analog, such as gemcitabine, fluorouracil (5-FU), cytarabine, mercaptopurine, azacytidine, cladribine, decitabine, fluorouracil, floxuridine, fludarabine, nilarabine, azathioprine, allopurinol, trimethoprim, lamivudine, emtricitabine, telbivudine, tenofovir, adefovir, feraluridine, didanosine (dideoxyinosine: ddI), zalcitabine (dideoxycytidine: ddC), stavudine (d4T) or zidovudine (AZT). In certain embodiments, the aptamer may be conjugated to nanoparticles such as dendrimers or lipid-based nanoparticles. In certain embodiments, the nanoparticles or dendrimers may comprise anti-tumor chemicals, such as siBCL3, siPRMT5, and siMAT2A; siRNAs, such as siBCL3, siPRMT5, and siMAT2A; antibodies, such as alemtuzumab, atezolizumab, avelumab, bevacizumab, blinatumomab, brentuximab, cemiplimab, cetuximab, daratumumab, Tocumab, datuximab, durvalumab, elotuzumab, gemtuzumab, olizumab, ipilimumab, moglizumab, mosetumab, necituzumab, nivolumab, ofatumumab, olaratumumab, panitumumab, pembrolizumab, pertuzumab, ramucirumab, rituximab, tositumomab, and trastuzumab; alkylating agents such as altretinoin, bendamustine, busulfan anisidine, carmustine, chlorambucil, cyclophosphamide, dacarbazine, ifosfamide, lomustine, lomustine, melphalan, procarbazine, streptozotocin, temozolomide, thiotepa, and trabectedin; platinum coordination complexes, such as carboplatin, cisplatin, and oxaliplatin; antibiotics, such as bleomycin, dactinomycin, daunorubicin, doxorubicin, epirubicin, idarubicin, mitomycin, mitoxantrone, plicamycin, and valrubicin ; antifolates, such as methotrexate, pemetrexed, pralatrexate, and trimetrexate; purine analogs, such as azathioprine, cladribine, fludarabine, and mercaptopurine; pyrimidine analogs, such as azacitidine, capecitabine, cytarabine, decitabine, floxuridine, fluorouracil, gemcitabine, and trifluridine / tiprazil; biological response modifiers, such as interleukin (IL-2), denileukin, and interferon gamma;Histone deacetylase inhibitors, such as belinostat, panobinostat, romidepa, and vorinostat; antiandrogens, such as abiraterone, apalutamide, bicalutamide, cyproterone acetate, enzalutamide, flutamide, and nilutamide; antiestrogens (including aromatase inhibitors), such as anastrozole, exemestane, fulvestrant, letrozole, raloxifene, tamoxifen, and toremifene; gonadotropin-releasing hormone analogs, such as degarelix, goserelin, histrelin, leuprolide, and triptolide alerelin; peptide hormones such as lanreotide, octreotide, and pasireotide; protein kinase inhibitors such as abemaciclib, acalabrutinib, afatinib, alectinib, abelizumab, axitinib, bemetinib, bortezomib, bosutinib, brigatinib, cabozantinib, carfilzomib, ceritinib, cobimetinib, cupranisib, crizotinib, dabrafenib, dacomitinib, dasatinib, duvelisib, ensitinib, connefenib, entrectinib, erdafitinib, erlotinib, fizotinib, gemfibrate tinib, gilteritinib, gradizib, ibrutinib, idelalisib, imatinib, ivosidenib, ixazomib, lapatinib, larotrectinib, lenvatinib, lorlatinib, midostaurin, neratinib, nilotinib, niraparib, olaparib, osimertinib, palbociclib, pazopanib, pemidatinib, ponatinib, regorafenib, ribociclib, rucaparib, ruxolitinib, selumetinib, solidegib, sorafenib, sunitinib, talazopanib, trametinib, vandetanib , vemurafenib, vismodegib and zanubrutinib; topoisomerase inhibitors such as etoposide, irinotecan, teniposide and topotecan; vinca alkaloids such as vinblastine, vincristine and vinorelbine; and / or other compounds including asparaginase (pegaspargase), bexarotene, eribulin, everolimus, hydroxyurea, ixabepilone, lenalidomide, mitotane, omacetin, pomalidomide, talafos, terostat, temsirolimus, thalidomide and / or venetoclax, etc. In certain embodiments, some drugs contain thiol groups, such as 6-mercaptopurine (anti-cancer), captopril (antihypertensive), D-penicillamine (anti-arthritis), sodium methylsulfate (anti-arthritis), and can be used for conjugation with aptamers. In certain embodiments, aptamer conjugates can be used to deliver drugs (including drugs within nanoparticles) to specific locations in the subject's body, such as cancer cells. ;

[0076] Materials and methods

[0077] Non-malignant and cancerous nasopharyngeal epithelial cell lines

[0078] NP460 cells were cultured in 50% complete Eplife medium (Thermo Fisher Scientific) and 50% complete defined keratinocyte-SFM (ThermoFisher Scientific) containing 100 units / ml penicillin and 100 μg / ml streptomycin. NPC43 LMP1+ve cells and LMP1-ve cells were cultured in RPMI-1640 (Sigma) containing 10% fetal bovine serum, 4 μM Y27632 dihydrochloride (Alexis), 100 units / ml penicillin and 100 μg / ml streptomycin. HONE1-LMP1+ve cells were cultured in RPMI-1640 (Sigma) containing 10% fetal bovine serum, 100 units / ml penicillin and 100 μg / ml streptomycin. NPC43-EBV+ve cells and NPC43-EB V-ve cells were cultured in RPMI-1640 (Sigma) containing 10% fetal bovine serum, 4 μM Y27632 dihydrochloride (Alexis), 100 units / ml penicillin and 100 μg / ml streptomycin. C666-1 and A549 cells were cultured in RPMI-1640 (Sigma) containing 10% fetal bovine serum, 100 units / ml penicillin and 100 μg / ml streptomycin.

[0079] NPC xenografts

[0080] Male immunodeficient mice (NOD / SCID) aged 4 to 5 weeks were provided by the Laboratory Animal Unit (LAU) of the Chinese University of Hong Kong, China, and maintained under pathogen-free conditions. All animal experiments were performed under conditions approved by the Animal Ethics Committee (AEEC) of the Chinese University of Hong Kong, China and issued by the Department of Health of Hong Kong, China. To promote the growth of NPC43-LMP1+ve cell lines and LMP1-ve cell lines as tumor xenografts in mice, 1×10 7The cells were resuspended in 200 μl (1:1 mixture of Matrigel and culture medium) and injected subcutaneously in the left side of the dorsal region of each NOD / SCID mouse. For C15 tumor xenografts, the xenografts were cut into a semi-solid state and mixed with Matrigel in a 1:1 ratio and then implanted in the right side of the dorsal region of NOD / SCID mice. Once the tumors were palpable (4 to 6 mm in diameter), the mice were randomized to drug treatment or control groups. Apt-2019-5FU (2 μmol / kg) was dissolved in 200 μl of DPBS containing 5 mM MgCl2 and injected into the animals through the tail vein every two days. 5-FU was dissolved to 100 mM at a stock concentration and diluted with DPBS for tail vein injection every two days. Tumor size and animal weight were recorded daily throughout the treatment period. All mice were euthanized at the end of the experiment, and the tumors were excised and fixed with 10% neutral buffered formalin (NBF) for histopathological examination and immunohistochemical studies.

[0081] Cell viability assay

[0082] NPC cells were incubated in 96-well plates overnight at 1000 cells per well in 100 μl of culture medium. Apt-2019-5FU and 5-FU were dissolved in cell culture medium at doses ranging from 0 μM to 1 μM and added to NPC cells for 72 h. Cell Counting Kit 8 was used to detect cell viability according to the manufacturer's instructions.

[0083] Western blotting

[0084] Use from Transgen Cells were lysed using a mammalian total protein extraction kit (DE101-01) for western blot analysis. ProteinSafeTM protease inhibitor (Transgen, DI101-01) without EDTA (100×) was included in the protein extraction kit immediately before use. The dissolved protein samples were adjusted to the same protein concentration and separated by SDS–polyacrylamide gel electrophoresis. NC membrane (GE Healthcare, 0.45 μm) was used to transfer the dissolved proteins in the gel. Chemiluminescent signals were captured using a ChemiDoc MP imaging system (Bio-Rad) and detected by different antibodies against various proteins, including GAPDH (1:10000; Transgen, HC301-01), CNBP (1:3000; Abclone, 15110), MTDH (1:1000 Abclone, A5887), and LMP1 (1:3000, Dako, M0897).

[0085] Cell-SELEX

[0086] Cell-SELEX was performed according to the protocol of “Development of DNA aptamers using cell-SELEX”

[234] with some modifications. Briefly, the UNIQ-10 adsorption column oligonucleotide purification kit (sangon B511143) was used to extract and purify ssDNA after PCR amplification. Sequencing libraries were prepared by PCR using the aptamer pools from rounds 9 to 13 as templates. The libraries were sent to Guangzhou IGE Company for next-generation sequencing. The occurrence time of sequences in each library was counted and then listed from high to low according to the occurrence time. The top 100 sequences in each round were analyzed in ClustalW (see the global website: genome.jp / tools-bin / clustalw). Eight sequences were selected for further determination.

[0087] Flow cytometry

[0088] 10 μM aptamer or aptamer pool was dissolved in DBPS containing 5 mM MgCl2 as a stock solution and diluted to 200 nM with binding buffer (DBPS containing 5 mM MgCl2, 0.1% BSA, 100 mg of tRNA and 0.45% glucose), then heated at 95°C for 5 minutes and cooled on ice for 5 minutes. The cells were trypsinized and incubated in the aptamer solution at 4°C for 30-60 minutes. After incubation, the cells were washed once with pre-cooled binding buffer. Finally, the samples were analyzed using a BD flow cytometer. For flow cytometric analysis of particle assays, NTA particles were incubated with cell lysates containing CNBP-his or MTDH-his or control lysates at 4°C for 1 hour and then washed 3 times with binding buffer. Afterwards, the particles were incubated with FAM-Apt-2019 or FAM-Apt-1194 (200 nM) at 4°C for 30 minutes. Finally, the particle-aptamer complexes were washed three times with binding buffer and analyzed using a BD flow cytometer.

[0089] Confocal microscopy imaging

[0090] For live cell imaging, NPC43-LMP1+ and NPC43-LMP1- cells were seeded in 3.5 cm confocal dishes 24 h before. Cells were washed twice with PBS and then incubated with 200 nM aptamer in binding buffer for 30 min, followed by washing twice with DPBS. Zeiss LSM880 was used to capture confocal images. For immunofluorescence and aptamer co-staining, cells were fixed with 4% PFA for 15 min and then blocked with 3% BSA for 1 h. CNBP antibody was incubated with cells at a 1:100 dilution (Abclone, 15110) for 1 h, followed by incubation with anti-rabbit Alex-555 antibody (1:500) for 1 h. After washing 3 times, FAM-Apt-2019 was added and incubated for 1 h.

[0091] Pull-down assay and mass spectrometry

[0092] Pull-down assays were performed according to the protocol of Shangguan Laboratory [235-237]. Protein samples were then separated in PAGE gels and stained with the Pierce Silver Staining Kit from Life Technology. Specific bands of approximately 20 kDa or 70 kDa were sent to the Biotechnology Company (Beijing) Branch for mass spectrometry analysis.

[0093] G-quadruplex (G4) structure determination

[0094] Thioflavin T (ThT) is a G4 ligand dye, and its fluorescence signal increases after binding to the G4 structure. Therefore, it is widely used in the detection of G4 structure. Apt-2019 performs ThT staining in the presence of Li+ or K+. Circular dichroism (CD) chromatography is used to determine the G4 isoform structure.

[0095] Synthesis of aptamers

[0096] The aptamer sequences were synthesized by Guangzhou IGE, Huzhou Ship and Kunshan Biotechnology Company.

[0097] All patents, patent applications, provisional applications, and publications (including figures and tables) mentioned or cited herein are incorporated by reference in their entirety to the extent not inconsistent with the explicit teachings of this specification.

[0098] The following are examples illustrating the process of practicing the present invention. These examples should not be construed as limiting. Unless otherwise indicated, all percentages are by weight and all solvent mixture ratios are by volume.

[0099] Example 1 - Enrichment of aptamers with high binding affinity to LMP1 / EBV positive cells after cell-SELEX.

[0100] Given the unique relevance of EBV infection in NPC pathogenesis, we have discovered aptamers enriched from cell-SELEX using positive and negative pairs with (A) LMP1 overexpression or (B) EBV-infected NPC43.

[0101] (A) Discovery of aptamers targeting cells expressing LMP1:

[0102] Identification of Apt-2019 that preferentially binds to cells expressing LMP1. noEBV 12 rounds of cell-SELEX were performed on the cells, while vector control cells were used in negative selection. Flow cytometric analysis showed that NPC43 bound to FAM-labeled aptamers enriched from the 9th, 11th, and 12th rounds of cell-SELEX noEBV -LMP1NPC43noEBV-LMP1 cells gradually increased the fluorescence signal ( Figure 1A ), indicating that the enrichment process was successful. The sequences of the enriched aptamers were then identified by next generation sequencing (NGS). The top 100 sequences were selected by CLUSTALW for multiple sequence alignment (see global website: genome.jp / tools-bin / clustalw). Eight sequences were selected based on sequence similarity and abundance of sequence reads. Among them, aptamer-2019 (Apt-2019) showed the ability to express LMP1 in cells ( Figure 1B )'s highest priority combination ( Figure 1B ). The specific binding ability of Apt-2019 was also confirmed in multiple LMP1-transfected cell lines, including HONE1, C17, and NP460. Apt-2019 preferentially binds to all of these LMP1-overexpressing cells compared to vector control cells.

[0103] Example 2 - CCHC zinc finger nucleic acid binding protein (CNBP) is the binding target of Apt-2019

[0104] To identify the target surface protein bound by Apt-2019 on cells expressing LMP1, we performed a pull-down assay using Apt-2019. When compared with the Apt-library (random sequence), a specific band of approximately 20 kd was observed in the silver-stained gel after electrophoresis of the pulled-down proteins by Apt-2019 ( Figure 2A ). Proteins from this band were purified from the gel and protein identification was performed by tandem mass spectrometry (MS / MS). CNBP was found to be a potential target of Apt-2019. To verify that CNBP is a target of Apt-2019, the pull-down proteins from Apt-2019 and Apt-library in LMP1 cell lysates were blotted with antibodies against CNBP ( Figure 2A The docking model between Apt-2019 and CNBP was also predicted by HDOCK (see global website: hdock.phys.hust.edu.cn / )( Figure 2A Another validation assay was performed by flow analysis of CNBP-labeled and CNBP-unlabeled particles after binding to Apt-2019-FAM ( Figure 2B ). Apt-2019 can specifically bind to CNBP-labeled particles. In addition, Apt-2019-bound CNBP is specifically expressed on the cell surface, as the fluorescent signals of CNBP and Apt-2019 are both localized on "non-permeabilized" NPC43-LMP1 cells. ( Figure 3A ). Notably, surface and total expression of CNBP was upregulated in cells overexpressing LMP1 ( FIG. 3A to FIG. 3B ). In addition, CRISPR knockout of CNBP in NPC cells inhibited the binding of Apt-2019 ( Figure 3C Western blot analysis showed that CNBP was highly expressed in the membrane fraction of NPC43-LMP1 cells ( Figure 3D ). All of these confirmed that Apt-2019 can bind to cell surface CNBP on NPC cells. Importantly, CNBP is overexpressed in EBV-associated NPC cell lines, PDXs, and primary NPC tissues, but not in immortalized NP cells ( FIG. 3E to FIG. 3F ). To understand the function of CNBP, we knocked out CNBP in NPC cells. In the case of CNBP knockout, decreased proliferation and migration abilities were observed ( Figure 3G to Figure 3H ).

[0105] Example 3 - Identification of Apt-1194 and Apt-1798 that preferentially bind to EBV-positive cells

[0106] In this part, we used a combination of cell-SELEX and in vivo SELEX to select cell surface-binding aptamers that can be enriched in EBV-positive NPC tumors in vivo. noEBV ') 12 rounds of cell-SELEX ( Figure 4A After 12 rounds of cell-SELEX, the enriched aptamers were then injected into mice bearing NPC43 subcutaneous tumors via tail vein. The aptamers accumulated in the tumors were then eluted by PCR amplification and re-injected into mice bearing NPC43 ( Figure 4A ). The enriched aptamers in vivo were then sent to next generation sequencing. The first two enriched aptamers (Apt-1194 and Apt-1798) were then identified.

[0107] Example 4—MTDH is a binding target of Apt-1194

[0108] The specificity of Apt-1194 for EBV-positive cells was confirmed by binding of Apt-1194 and Apt-1798 to a panel of EBV-positive NPC cell lines (NPC43, C666-1, and C17), an EBV-negative lung cancer cell line (A549), and a nasopharyngeal cell line (NP460). Figure 4B ). Proteins from NPC43 lysates were pulled down by Apt-1194. After gel electrophoresis, protein purification, and mass spectrometry analysis, MTDH was found to be the target of Apt-1194 by Western blotting ( Figure 4C MTDH has been reported to be a prognostic marker for NPC (19). We also observed overexpression of MTDH in NPC cell lines, PDX, and primary NPC tissues ( FIG. 4D to FIG. 4E ), indicating that Apt-1194 can serve as an NPC-targeting aptamer. Knockout of MTDH can inhibit the proliferation and migration ability of NPC cells ( Figure 4F ).

[0109] Example 5 - Apt-2019 and Apt-1194 are G-quadruplexes with high serum stability and can be rapidly internalized into cells

[0110] Apt-2019 and Apt-1194 are both guanine-rich oligonucleotides (GROs) with G contents of 43% and 41%, respectively. GROs can form stable G-quadruplex structures because four guanine bases form a square planar structure called a G-tetrad through Hoostein base pairing, and these G-tetrads spontaneously assemble into a four-stranded helical structure called a G-quadruplex (G4) ( Figure 5A )(20). It is well known that oligonucleotides that form G4 are relatively stable and not subject to nuclease degradation (21). Therefore, we examined whether Apt-2019 and Apt-1194 can form G4 using thioflavin T (ThT) as a fluorescent luminescent probe for G4 formation (22). In the presence of lithium cacodylate buffer or potassium phosphate buffer, both aptamers folded into G4, allowing ThT ligand binding and fluorescence emission ( FIG. 5B to FIG. 5C ). Therefore, Apt-2019 and Apt-1194 have higher serum stability than random non-GC-enriched aptamers ( Figure 5D ) can be explained by their stable G4 structure. To further characterize these novel NPC-targeting aptamers, we measured their equilibrium dissociation constants (Kd). Their nanomolar range of Kd indicates high binding affinity to NPC cells ( FIG. 5E to FIG. 5FImportantly, Z-stack confocal microscopy also revealed that Apt-2019 could be internalized into LMP1-expressing NPC43 cells ( Figure 5G ). Similar internalization of Apt-1194 was also observed after incubation with EBV-positive NPC cells.

[0111] Example 6 - Apt-2019 and Apt-1194 as imaging probes for nasopharyngeal carcinoma tumors in vivo

[0112] Fluorescently labeled Apt-2019 and Apt-1194 were injected into the tail vein of mice bearing C15 tumors (NPC xenografts with high LMP1 expression (18)) and EBV-positive C666-1 tumors, respectively. We also generated control aptamers against Apt-2019 and Apt-1194 by replacing all Gs with Cs, thereby impairing the ability to form G4. The resulting control aptamer was named Apt-NG. 2019 (SEQ ID NO:4; Apt-NG 2019(14-63) Aptamer: CAGCAGAATCCGTGCCATTCCTCAGACCGGTTCCTGAGTTTGTGATGGAC) and Apt-NG 1194 (SEQ ID NO:5; Apt-NG 1194(1-58) Aptamer: ATCCAGAGTGACGCAGCACCGAGCGAGTTGGTTTGCTGCCCTGCCCAGA GACCTGGCC). Tumors and organs (such as lungs and spleen) were removed for fluorescence imaging (IVIS Spectrum Imager). FIG. 6A to FIG. 6B Representative images of Apt-2019 or Apt-1194 (but not the control Apt-NG aptamer) accumulation in tumors are shown.

[0113] Example 7—Toxicity of drug-loaded aptamers targeting EBV-associated NPC cells

[0114] Gemcitabine (Gem) and fluorouracil (5-FU), which have structures similar to natural nucleotides, can be enzymatically incorporated into DNA chains ( Fig. 7A (23)). These therapeutic drugs can be released in situ after aptamer hydrolysis and escape from lysosomes via active nucleotide transporters such as equilibrative nucleoside transporter 3 (ENT3). The incorporation of Gem or 5-FU into our NPC-targeting aptamers produced bifunctional aptamers with enhanced binding affinity and toxicity. In our preliminary data, we have replaced all T nucleotides in Apt-2019 with 5-FU and all C nucleotides in Apt-1194 with Gem. By performing flow cytometry analysis, drug-loaded Apt-2019 and drug-loaded Apt-1194 still preferentially bound to target cells ( FIG. 7B to FIG. 7C ). In addition, these drug-loaded aptamers are 50 About 50nM is cytotoxic to NPC cells ( FIG. 7D to FIG. 7E ).

[0115] Example 8 - By loading 5-FU into APt-2019, the effective dose in vivo can be lowered by >10-fold

[0116] We have examined the in vivo antitumor effects of free 5-FU and Apt-2019-5FU when the same dose of 5-FU (20 μmol / kg mouse every two days; 20 μmol 5-FU = 2.6 mg 5-FU) was used in both treatment groups ( Fig. 8A ). It must be emphasized that this dose is approximately 11.5 times lower than the normal effective dose of 5-FU for tumor treatment (30 mg / kg / every two days) in mouse models (24,25). Apt-2019-5FU can effectively inhibit tumor growth, while free 5-FU has little inhibitory effect ( Fig. 8A Importantly, the morphology of the liver, spleen, kidneys, and body weight did not change significantly among the three groups ( FIG. 8B to FIG. 8C ). The genomic sequence of CNBP is identical in mice and humans. All of this suggests that the CNBP-mediated targeting of Apt-2019-5FU to NPC tumors did not cause any observable side effects to the treated organism. Another similar experiment was conducted using a xenograft-C15 with high expression of LMP1. Apt-2019-5FU was also very effective in inhibiting tumor growth ( Fig.8D ). All these results suggest that Apt-2019 can enhance the efficacy of 5-FU by effectively targeting 5-FU to NPC tumors in vivo.

[0117] It should be understood that the examples and embodiments described herein are for illustrative purposes only, and that those skilled in the art may make various modifications or changes based on these examples and embodiments, which should be included in the spirit and scope of the present application and the scope of the appended claims. In addition, any element or limitation of any invention or embodiment disclosed herein may be combined with any and / or all other elements or limitations disclosed herein (alone or in any combination) or any other invention or embodiment, and all such combinations are within the scope of the present invention but are not limited thereto.

[0118] Example

[0119] Example 1. An isolated DNA oligonucleotide aptamer according to SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3, or an oligonucleotide having at least 90% identity to SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3.

[0120] Embodiment 2. The DNA oligonucleotide aptamer according to embodiment 1, wherein the DNA oligonucleotide aptamer binds to CCHC-type zinc finger nucleic acid binding protein (CNBP) and / or metahesin (MTDH).

[0121] Embodiment 3. The DNA oligonucleotide aptamer according to embodiment 1, wherein the DNA oligonucleotide aptamer is conjugated with a fluorescent group, a thiol group, biotin or an enzyme.

[0122] Embodiment 4. The DNA oligonucleotide aptamer according to embodiment 3, wherein the fluorescent group, the thiol group, the biotin or the enzyme is conjugated to the 5' end of the DNA oligonucleotide aptamer.

[0123] Embodiment 5. The DNA oligonucleotide aptamer according to embodiment 1, wherein the one or more DNA oligonucleotide aptamers are conjugated with one or more nucleoside analogs or anticancer nanoparticles.

[0124] Embodiment 6. The DNA oligonucleotide aptamer according to embodiment 5, wherein the one or more nucleoside analogs are 5-FU, gemcitabine, cytarabine, mercaptopurine, azacytidine, cladribine, decitabine, fluorouracil, floxuridine, fludarabine, nilarabine, azathioprine, allopurinol, trimethoprim, lamivudine, emtricitabine, telbivudine, tenofovir, adefovir, fedaruridine, didanosine (dideoxyinosine, ddI), zalcitabine (dideoxycytidine: ddC), stavudine (d4T) or zidovudine (AZT).

[0125] Embodiment 7. The DNA oligonucleotide aptamer according to embodiment 5, wherein the anticancer nanoparticles comprise antibodies, antitumor compounds, siRNA, alkylating agents, platinum coordination complexes, antibiotics, antifolate agents, purine analogs, pyrimidine analogs, biological response modifiers, histone deacetylase inhibitors, antiandrogens, antiestrogens, gonadotropin-releasing hormone analogs, peptide hormones, protein kinase inhibitors, topoisomerase inhibitors, vinca alkaloids, asparaginase, bexarotene, eribulin, everolimus, hydroxyurea, ixabepilone, lenalidomide, mitotane, omacetin, pomalidomide, talafosse, terostat, temsirolimus, thalidomide, venetoclax, or any combination thereof.

[0126] Embodiment 8. A composition comprising one or more DNA oligonucleotide aptamers according to embodiment 1.

[0127] Embodiment 9. The composition according to embodiment 8, wherein the one or more DNA oligonucleotide aptamers are conjugated with a fluorescent group, a thiol group, biotin or an enzyme.

[0128] Embodiment 10. The composition according to embodiment 8, wherein the one or more DNA oligonucleotide aptamers are conjugated to one or more nucleoside analogs or anticancer nanoparticles.

[0129] Embodiment 11. The composition of embodiment 10, wherein the one or more nucleoside analogs are 5-FU, gemcitabine, cytarabine, mercaptopurine, azacytidine, cladribine, decitabine, fluorouracil, floxuridine, fludarabine, nilarabine, azathioprine, allopurinol, trimethoprim, lamivudine, emtricitabine, telbivudine, tenofovir, adefovir, fedaruridine, didanosine, zalcitabine, d4T or AZT.

[0130] Embodiment 12. The composition according to embodiment 10, wherein the anticancer nanoparticles comprise antibodies, anticancer compounds, siRNA, alkylating agents, platinum coordination complexes, antibiotics, antifolate agents, purine analogs, pyrimidine analogs, biological response modifiers, histone deacetylase inhibitors, antiandrogens, antiestrogens, gonadotropin-releasing hormone analogs, peptide hormones, protein kinase inhibitors, topoisomerase inhibitors, vinca alkaloids, asparaginase, bexarotene, eribulin, everolimus, hydroxyurea, ixabepilone, lenalidomide, mitotane, omacetin, pomalidomide, talafosse, terostat, temsirolimus, thalidomide, venetoclax, or a combination of any one of them.

[0131] Embodiment 13. The composition according to embodiment 8, wherein the composition further comprises a pharmaceutically acceptable carrier and / or excipient.

[0132] Example 14. A method for imaging cancer cells in a subject, the method comprising:

[0133] i) administering to the subject one or more DNA oligonucleotide aptamers according to claim 1, wherein the one or more DNA oligonucleotide aptamers are conjugated or linked to a biocompatible imaging probe; and

[0134] ii) measuring the probe signal level of the DNA oligonucleotide aptamer binding to the target.

[0135] Embodiment 15. The method according to embodiment 14, wherein the biocompatible imaging probe is 18F-FDG, 64Cu-NOTA, 11С-methionine or 11С-choline.

[0136] Embodiment 16. The method according to embodiment 14, wherein the DNA oligonucleotide aptamer is administered intravenously.

[0137] Embodiment 17. The method according to embodiment 14, wherein the DNA oligonucleotide adaptor binds to CNBP and / or MTDH.

[0138] Embodiment 18. A method of treating cancer, comprising administering to the subject one or more DNA oligonucleotide aptamers according to Embodiment 1, wherein the one or more DNA oligonucleotide aptamers are conjugated to a drug.

[0139] Embodiment 19. The method according to embodiment 18, wherein the drug is a nucleoside analog or an anticancer nanoparticle.

[0140] Embodiment 20. The method of embodiment 19, wherein the nucleoside analog is 5-FU, gemcitabine, cytarabine, mercaptopurine, azacytidine, cladribine, decitabine, fluorouracil, floxuridine, fludarabine, nilarabine, azathioprine, allopurinol, trimethoprim, lamivudine, emtricitabine, telbivudine, tenofovir, adefovir, fedaruridine, didanosine, zalcitabine, d4T or AZT.

[0141] Embodiment 21. The composition according to embodiment 19, wherein the anticancer nanoparticles comprise antibodies, anticancer compounds, siRNA, alkylating agents, platinum coordination complexes, antibiotics, antifolate agents, purine analogs, pyrimidine analogs, biological response modifiers, histone deacetylase inhibitors, antiandrogens, antiestrogens, gonadotropin-releasing hormone analogs, peptide hormones, protein kinase inhibitors, topoisomerase inhibitors, vinca alkaloids, asparaginase, bexarotene, eribulin, everolimus, hydroxyurea, ixabepilone, lenalidomide, mitotane, omacetin, pomalidomide, talafosse, terostat, temsirolimus, thalidomide, venetoclax, or a combination of any one of them.

[0142] Embodiment 22. The method of embodiment 18, wherein the cancer is nasopharyngeal carcinoma, breast cancer, pancreatic cancer, bladder cancer, colorectal cancer, endometrial cancer, kidney cancer, leukemia, liver cancer, lung cancer, melanoma or gastric cancer.

[0143] Embodiment 23. The method according to embodiment 18, wherein the DNA oligonucleotide aptamer binds to CNBP and / or MTDH.

[0144] References

[0145] 1. Byun J. Recent Progress and Opportunities for Nucleic Acid Aptamers. Life (Basel). 2021; 11(3).

[0146] 2. Zhou J, Rossi J. Aptamers as targeted therapeutics: current potential and challenges. Nat Rev Drug Discov. 2017; 16(3): 181 - 202.

[0147] 3. Darmostuk M, Rimpelova S, Gbelcova H, Ruml T. Current approaches in SELEX: An update to aptamer selection technology. Biotechnology advances. 2015.

[0148] 4. Sefah K, Shangguan D, Xiong X, O'Donoghue MB, Tan W. Development of DNA aptamers using Cell - SELEX. Nature protocols. 2010; 5(6): 1169 - 85.

[0149] 5. Liang S, Kinghorn AB, Voliotis M, Prague JK, Veldhuis JD, Tsaneva - Atanasova K, McArdle CA, Li RHW, Cass AEG, Dhillo WS, Tanner JA. Measuring luteinising hormone pulsatility with a robotic aptamer - enabled electrochemical reader. Nat Commun. 2019; 10(1): 852.

[0150] 6.Cheung YW,Rothlisberger P,Mechaly AE,Weber P,Levi-Acobas F,Lo Y,Wong AWC,Kinghorn AB,Haouz A,Savage GP,Hollenstein M,Tanner JA.Evolution ofabiotic cubane chemistries in a nucleic acid aptamer allowsselectiverecognition of a malaria biomarker.Proc Natl Acad Sci U S A.2020;117(29):16790-8.

[0151] 7.Tang MSL,Shiu SC,Godonoga M,Cheung YW,Liang S,DirkzwagerRM,KinghornAB,Fraser LA,Heddle JG,Tanner JA.An aptamer-enabled DNAnanobox for proteinsensing.Nanomedicine.2018;14(4):1161-8.

[0152] 8.Chen YP,Chan ATC,Le QT,Blanchard P,Sun Y,Ma J.Nasopharyngealcarcinoma.Lancet.2019;394(10192):64-80.

[0153] 9.Rickinson AB,Lo KW.Nasopharyngeal carcinoma:AHistory.Nasopharyngeal Carcinoma:From Etiology to Clinical Practice AcademicPress,London,United Kingdom2019:1-13.

[0155] 10.Lee VHF,Lam KO,Lee AW.Standard of care for NasopharyngealCarcinoma(2018-2020).Nasopharyngeal Carcinoma:From Etiology to ClinicalPracticeAcademic Press,London,United Kingdom2019:206-37.

[0157] 11.Tsang CM,Lui VWY,Bruce JP,Pugh TJ,Lo KW.Translationalgenomics ofnasopharyngeal cancer.Semin Cancer Biol.2019.

[0158] 12.Li YY,Chung GT,Lui VW,To KF,Ma BB,Chow C,Woo JK,Yip KY,Seo J,HuiEP,Mak MK,Rusan M,Chau NG,Or YY,Law MH,Law PP,Liu ZW,Ngan HL,Hau PM,VerhoeftKR,Poon PH,Yoo SK,Shin JY,Lee SD,Lun SW,JiaL,Chan AW,Chan JY,Lai PB,Fung CY,Hung ST,Wang L,Chang AM,ChioseaSI,Hedberg ML,Tsao SW,van Hasselt AC,Chan AT,Grandis JR,Hammerman PS,Lo KW.Exome and genome sequencing of nasopharynxcancer identifiesNF-kappaB pathway activating mutations.Nat Commun.2017;8:14121.

[0159] 13.Lin DC, Meng X, Hazawa M, Nagata Y, Varela AM, Xu L, Sato Y, LiuLZ, DingLW,Sharma A,Goh BC,Lee SC,Petersson BF,Yu FG,Macary P,OoMZ,Ha CS,Yang H,OlandacK genomic K,TheefpeSKo,Loh ofnasopharyngeal carcinoma.NatGenet.2014;46(8):866-71.

[0160] Dai W,Zheng H,Cheung AK,Tang CS,Ko JM,Wong BW,Leong MM,Sham PC,Cheung F,Kwong DL,Ngan RK,Ng WT,Yau CC,Pan J,Peng X,TungS,Zhang Z,Ji M,ChiangLamKH,Lee KOH,Le AW. HC,YiuHH,Lung ML.Whole-exome sequencingidentifies MST1R as a geneticssusceptibility gene in nasopharyngealcarcinoma.Proc Natl Acad Sci US A.2016;113(12):3317-22.

[0161] 15.Bruce JP,To KF,Lui VWY,Chung GTY,Chan YY,Tsang CM,Yip KY,Ma BBY,Woo JKS,Hui EP,Mak MKF,Lee SD,Chow C,Velapasamy S,Or YYY,Siu PK,El GhamrasniS,Prokopec S,Wu M,Kwan JSH,Liu Y,Chan JYK,vanHasselt CA,Young LS,Dawson CW,Paterson IC,Yap LF,Tsao SW,Liu FF,ChanATC,Pugh TJ,Lo KW.Whole-genomeprofiling of nasopharyngeal carcinomareveals viral-host co-operation ininflammatory NF-kappaB activation and immuneescape.Nat Commun.2021;12(1):4193.

[0162] 16.Tsao SW,Tsang CM,Lo KW.Epstein-Barr virus infectionandnasopharyngeal carcinoma.Philos Trans R Soc Lond B Biol Sci.2017;372(1732).

[0163] 17.Dawson CW,Port RJ,Young LS.The role of the EBV-encodedlatentmembrane proteins LMP1 and LMP2 in the pathogenesis ofnasopharyngealcarcinoma(NPC).Semin Cancer Biol.2012;22(2):144-53.

[0164] 18.Tsao SW,Tsang CM,To KF,Lo KW.The role of Epstein-Barr virusinepithelial malignancies.The Journal of pathology.2015;235(2):323-33.

[0165] 19.Hui AB,Bruce JP,Alajez NM,Shi W,Yue S,Perez-Ordonez B,Xu W,O'Sullivan B,Waldron J,Cummings B,Gullane P,Siu L,Liu FF.Significanceofdysregulated metadherin and microRNA-375 in head and neck cancer.ClinCancerRes.2011;17(24):7539-50.

[0166] 20.Rhodes D,Lipps HJ.G-quadruplexes and their regulatory rolesinbiology.Nucleic Acids Res.2015;43(18):8627-37.

[0167] 21.Bishop JS,Guy-Caffey JK,Ojwang JO,Smith SR,Hogan ME,CossumPA,RandoRF,Chaudhary N.Intramolecular G-quartet motifs confer nucleaseresistance to apotent anti-HIV oligonucleotide.J Biol Chem.1996;271(10):5698-703.

[0168] 22.Renaud de la Faverie A,Guedin A,Bedrat A,Yatsunyk LA,MergnyJL.Thioflavin T as a fluorescence light-up probe for G4 formation.NucleicAcids Res.2014;42(8):e65.

[0169] 23.Xuan W,Peng Y,Deng Z,Peng T,Kuai H,Li Y,He J,Jin C,Liu Y,Wang R,Tan W.A basic insight into aptamer-drug conjugates(ApDCs).Biomaterials.2018;182:216-26.

[0170] 24.Lu Y,Huang H,Yang H,Chen D,Wu S,Jiang Z,Wang R.Smallmoleculeinhibitor TW-37 is tolerable and synergistic with chemotherapyinnasopharyngeal carcinoma.Cell Cycle.2017;16(14):1376-83.

[0171] 25.Zhang P,Lai ZL,Chen HF,Zhang M,Wang A,Jia T,Sun WQ,Zhu XM,Chen XF,Zhao Z,Zhang J.Curcumin synergizes with 5-fluorouracil by impairingAMPK / ULK1-dependent autophagy,AKT activity and enhancing apoptosis incolon cancer cellswith tumor growth inhibition in xenograft mice.J Exp ClinCancer Res.2017;36(1):190.

Claims

1. An isolated DNA oligonucleotide aptamer according to SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3, or an oligonucleotide having at least 90% identity to SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO:

3.

2. The DNA oligonucleotide aptamer according to claim 1, wherein the DNA oligonucleotide aptamer binds to CCHC-type zinc finger nucleic acid binding protein (CNBP) and / or metahesin (MTDH).

3. The DNA oligonucleotide aptamer according to claim 1, wherein the DNA oligonucleotide aptamer is conjugated with a fluorescent group, a thiol group, biotin or an enzyme. The DNA oligonucleotide aptamer according to claim 3 , wherein the fluorescent group, the thiol group, the biotin or the enzyme is conjugated to the 5′ end of the DNA oligonucleotide aptamer. 5 . The DNA oligonucleotide aptamer according to claim 1 , wherein the one or more DNA oligonucleotide aptamers are conjugated with one or more nucleoside analogs or anticancer nanoparticles.

6. The DNA oligonucleotide aptamer according to claim 5, wherein the one or more nucleoside analogs are 5-FU, gemcitabine, cytarabine, mercaptopurine, azacytidine, cladribine, decitabine, fluorouracil, floxuridine, fludarabine, nilarabine, azathioprine, allopurinol, trimethoprim, lamivudine, emtricitabine, telbivudine, tenofovir, adefovir, fedaruridine, didanosine (dideoxyinosine: ddI), zalcitabine (dideoxycytidine: ddC), stavudine (d4T) or zidovudine (AZT).

7. The DNA oligonucleotide aptamer according to claim 5, wherein the anticancer nanoparticles comprise antibodies, antitumor compounds, siRNA, alkylating agents, platinum coordination complexes, antibiotics, antifolate agents, purine analogs, pyrimidine analogs, biological response modifiers, histone deacetylase inhibitors, antiandrogens, antiestrogens, gonadotropin-releasing hormone analogs, peptide hormones, protein kinase inhibitors, topoisomerase inhibitors, vinca alkaloids, asparaginase, bexarotene, eribulin, everolimus, hydroxyurea, ixabepilone, lenalidomide, mitotane, omacetin, pomalidomide, talafosse, terostat, temsirolimus, thalidomide, venetoclax, or a combination of any one of them.

8. A composition comprising one or more DNA oligonucleotide aptamers according to claim 1.

9. The composition of claim 8, wherein the one or more DNA oligonucleotide aptamers are conjugated to a fluorescent group, a thiol group, biotin or an enzyme.

10. The composition of claim 8, wherein the one or more DNA oligonucleotide aptamers are conjugated to one or more nucleoside analogs or anticancer nanoparticles.

11. The composition of claim 10, wherein the one or more nucleoside analogs are 5-FU, gemcitabine, cytarabine, mercaptopurine, azacytidine, cladribine, decitabine, fluorouracil, floxuridine, fludarabine, nilarabine, azathioprine, allopurinol, trimethoprim, lamivudine, emtricitabine, telbivudine, tenofovir, adefovir, fedaruridine, didanosine, zalcitabine, d4T or AZT.

12. The composition of claim 10, wherein the anticancer nanoparticles comprise antibodies, anticancer compounds, siRNA, alkylating agents, platinum coordination complexes, antibiotics, antifolate agents, purine analogs, pyrimidine analogs, biological response modifiers, histone deacetylase inhibitors, antiandrogens, antiestrogens, gonadotropin-releasing hormone analogs, peptide hormones, protein kinase inhibitors, topoisomerase inhibitors, vinca alkaloids, asparaginase, bexarotene, eribulin, everolimus, hydroxyurea, ixabepilone, lenalidomide, mitotane, omacetin, pomalidomide, talafosse, terostat, temsirolimus, thalidomide, venetoclax, or a combination of any one of them.

13. The composition according to claim 8, wherein the composition further comprises a pharmaceutically acceptable carrier and / or excipient.

14. A method of imaging cancer cells in a subject, the method comprising: i) administering to the subject one or more DNA oligonucleotide aptamers according to claim 1, wherein the one or more DNA oligonucleotide aptamers are conjugated or linked to a biocompatible imaging probe; and ii) measuring the probe signal level of the DNA oligonucleotide aptamer binding to the target.

15. The method of claim 14, wherein the biocompatible imaging probe is 18F-FDG, 64Cu-NOTA, 11С-methionine or 11С-choline.

16. The method of claim 14, wherein the DNA oligonucleotide aptamer is administered intravenously.

17. The method according to claim 14, wherein the DNA oligonucleotide adaptor binds to CNBP and / or MTDH.

18. A method for treating cancer, the method comprising administering to the subject one or more DNA oligonucleotide aptamers according to claim 1, wherein the one or more DNA oligonucleotide aptamers are conjugated to a drug.

19. The method of claim 18, wherein the drug is a nucleoside analog or an anticancer nanoparticle.

20. The method of claim 19, wherein the nucleoside analog is 5-FU, gemcitabine, cytarabine, mercaptopurine, azacytidine, cladribine, decitabine, fluorouracil, floxuridine, fludarabine, nilarabine, azathioprine, allopurinol, trimethoprim, lamivudine, emtricitabine, telbivudine, tenofovir, adefovir, fedaruridine, didanosine, zalcitabine, d4T or AZT.

21. The method of claim 19, wherein the anticancer nanoparticles comprise antibodies, anticancer compounds, siRNA, alkylating agents, platinum coordination complexes, antibiotics, antifolate agents, purine analogs, pyrimidine analogs, biological response modifiers, histone deacetylase inhibitors, antiandrogens, antiestrogens, gonadotropin-releasing hormone analogs, peptide hormones, protein kinase inhibitors, topoisomerase inhibitors, vinca alkaloids, asparaginase, bexarotene, eribulin, everolimus, hydroxyurea, ixabepilone, lenalidomide, mitotane, omacetin, pomalidomide, talafosse, terostat, temsirolimus, thalidomide, venetoclax, or a combination of any one thereof.

22. The method of claim 18, wherein the cancer is nasopharyngeal carcinoma, breast cancer, pancreatic cancer, bladder cancer, colorectal cancer, endometrial cancer, kidney cancer, leukemia, liver cancer, lung cancer, melanoma, or gastric cancer.

23. The method of claim 18, wherein the DNA oligonucleotide adaptor binds to CNBP and / or MTDH.

Citation Information

Cited By

  • Aptamer probe for targeting EpCAM as well as preparation method and application of aptamer probe

    CN119564873A